

# Results and Outcome Reporting In ClinicalTrials.gov, What Makes it Happen?

Olga Kirillova\*

IICOLL LLC, Portland, Oregon, United States of America

## Abstract

**Background:** At the end of the past century there were multiple concerns regarding lack of transparency in the conduct of clinical trials as well as some ethical and scientific issues affecting the trials' design and reporting. In 2000 ClinicalTrials.gov data repository was developed and deployed to serve public and scientific communities with valid data on clinical trials. Later in order to increase deposited data completeness and transparency of medical research a set of restrains had been imposed making the results deposition compulsory for multiple cases.

**Methods:** We investigated efficiency of the results deposition and outcome reporting as well as what factors make positive impact on providing information of interest and what makes it more difficult, whether efficiency depends on what kind of institution was a trial sponsor. Data from the ClinicalTrials.gov repository has been classified based on what kind of institution a trial sponsor was. The odds ratio was calculated for results and outcome reporting by different sponsors' class.

**Results:** As of 01/01/2012 118,602 clinical trials data deposits were made to the depository. They came from 9068 different sources. 35344 (29.8%) of them are assigned as FDA regulated and 25151 (21.2%) as Section 801 controlled substances. Despite multiple regulatory requirements, only about 35% of trials had clinical study results deposited, the maximum 55.56% of trials with the results, was observed for trials completed in 2008.

**Conclusions:** The most positive impact on depositing results, the imposed restrains made for hospitals and clinics. Health care companies showed much higher efficiency than other investigated classes both in higher fraction of trials with results and in providing at least one outcome for their trials. They also more often than others deposit results when it is not strictly required, particularly, in the case of non-interventional studies.

**Citation:** Kirillova O (2012) Results and Outcome Reporting In ClinicalTrials.gov, What Makes it Happen? PLoS ONE 7(6): e37847. doi:10.1371/journal.pone.0037847

**Editor:** Laxmaiah Manchikanti, University of Louisville, United States of America

**Received:** February 20, 2012; **Accepted:** April 25, 2012; **Published:** June 13, 2012

**Copyright:** © 2012 Olga Kirillova. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** The author has no support or funding to report.

**Competing Interests:** The author is a founder of IICOLL Limited Liability Company. This does not alter the author's adherence to all the PLoS ONE policies on sharing data and materials.

\* E-mail: olga@iicoll.com

## Introduction

Clinical studies are important and one of the biggest part of modern health care research in US. Besides they are ones of the most expensive and, dealing with human subject and people health, required to be done with a special care. At the end of the past century there were multiple concerns regarding lack of transparency in the conduct of clinical trials as well as some ethical and scientific issues affecting the trials' design and reporting [1,2]. In response on request to increase transparency of medical research and novel drugs development, the Food and Drug Administration issued a Modernization Act, Section 113 of which required the development of a data registry [3]. So, in February 2000 ClinicalTrials.gov data repository was developed and deployed (Zarin, 2010 *Everything You Ever Wanted to Know About ClinicalTrials.gov, on-line presentation*). At that time it was designed to help potential participants find trials, and was primarily focused on people with serious or life-threatening conditions. Since then through careful review process it was substantially improved to become more complete and accurate. In September 2007 Food and Drug Administration Amendments Act (FDAAA) was enacted

with a legal requirement of trials registration for a broader group of trials than had previously been required under FDAMA [4]. In 2008, a database for reporting summary results was added to the registry [5]. Today technological advancement in large scale data processing, internet speed and cheap and getting cheaper electronic storage devices gives us an opportunity to deal with large scale data obtained from multiple sources and get a bigger picture of a clinical study.

In recent years there were several papers related to clinical trials: general reviews of clinical data repository ClinicalTrials.gov progress and development [5–7], investigation on how likely and soon a trial registered with ClinicalTrials.gov will result in a peer reviewed publication [8,9], concerns related to completeness of an outcome in the trials reporting [10], and rigorous study of comparative effectiveness and its relationship to funding sources [11].

Characteristic feature of the previous research is that one or other kind of selection has been performed rather than meta-analysis of all data available. Another point with lack of attention, in our opinion, is classification of institutions sponsoring/ conducting a trial.

In this study we performed overall meta-analysis of the clinical trials deposited into ClinicalTrials.gov repository as of January 1, 2012; developed advanced classification of trials sponsors and compare the results for different classes in two most important aspects of the deposited information: outcome reporting and deposition of clinical results data. Also we tried to decipher what factors make the results and outcome reporting more plausible or more difficult and whether it depends on the sponsor.

## Methods

### Data

Now significant number of clinical study records got public and everybody can download them from the site in a well structured format that makes the data processing easier and allows to keep the original structure and reduce potential errors usually occurring when plain text data need to be processed. We took the opportunity downloaded, processed and analyzed the data trying to decipher interesting regularities and to gain insight into the state of clinical research.


Data has been obtained from ClinicalTrials.gov repository. The last update has been done on 01/01/2012 and should contain all the clinical trials records as of the pointed date. The data were downloaded and imported into an in-house database. They were obtained in XML format, so all preexisting formatting has been saved. Parsing has been done by in-house developed *perl* script utilizing XML::Simple library for ease of XML parsing.

### Enhancement and Information Retrieval

While different kind of institutions take part in clinical research, they can be one of two types: for- or non-profit. Moreover, non-profit institutes are far non homogeneous among themselves, they can have fairly different goals, primary duties, and follow different kind of regulations. So, in relation to a clinical trial the difference between a national institute and a hospital may be as big as between a university and a pharmaceutical company. Therefore, in the presented study non-profits have been further subdivided into four classes: Research/Educational Institutions (**edu**) consisting of universities, colleges, academia, and other alike institutes primarily focused on research and education; Hospitals & clinics (**hos**) - organizations with primary focus on providing health care service for people with health issues; collaborations including associations, networks and other non-government institutions able to include in itself different kind of participants (**col**) and national and government organizations (**gov**). For-profit sponsors were put into one class (**com**), including itself pharmaceutical and other commercial companies of health care sector conducted and deposited trials' data. Classification schema is shown in Fig. 1. One has to note that the original data had sponsors classification. Namely, original classification had four classes: 'Industry', 'NIH', 'Other', and 'U.S. Fed.' We enhanced and slightly altered it in the way that 'NIH' and 'U.S. Fed.' classes were joined into one class (**gov**). This class was extended to include other non US national and governments sponsored institutions. (**com**) class is quite consistent with 'Industry' in the original classification. And 'Other' has been distributed primarily into **col**, **hos** and **edu** classes.

Classification has been performed by in house text-mining classifier designed as:

1. define keywords for a given class (like 'University', 'College', 'Università', etc. for **edu** class; 'Hospital', 'Clinics', 'Hôpitaux', 'Klinik', etc. for **hos** class; 'Company', 'Inc.', 'Corp.', etc. for companies);
2. make dictionaries for each class;



**Figure 1. Schema of the classification.**

doi:10.1371/journal.pone.0037847.g001

3. define priorities, like 'Hospital' has higher priority than 'University' or 'College' in other words 'University Hospital' will be classified as **hos** rather than **edu**.

We passed all records through the classifier, with supplementary classification of records, which did not pass through, using agency class information from original classification of the sponsors. We used a leading sponsor of the trial in the classification. Then partial manual inspection and corrections were made.

So, we got trials distribution into classes as shown in Table 1.

Overall correspondence between the depository classification and one described in this paper is shown in Table 2.

One has to note, that it is very tricky to make a precise classification for over 118,000 trials coming from over 9,000 different sources, especially taking into account that deposits have been made from different countries and therefore, the sponsors are pointed in different languages. Besides, as it often happens, the texts may have multiple typographic errors. So, eventually our classification may have some errors but we do believe that it is not significant taking into account the set size. After the automatic classification manual refinement of the results has been made.

### Statistical Analysis

Since 1951 medical statisticians use the odds ratio (OR) as a measure of effect size, to describe the strength of association or non-independence between two binary data characteristics [12]. It is used as a descriptive statistic, where results are rather qualitative than quantitative or an answer on a question is either 'yes' or 'no'. That perfectly suits our research of reporting clinical trials results and outcomes (for each trial one either has been reported or not). Additional beneficial feature of the odds ratio for our study is that it can be estimated using some types of non-random samples. The trials in the depository are definitely non-random taking into account that one sponsor usually deposits more than one trial.

So, we performed the odds ratio calculation as

$$OR = \frac{p_{11}p_{00}}{p_{10}p_{01}}$$

where  $p_{yx}$  comes from the joint distribution of two binary random variables  $X$  and  $Y$

	Y = 1	Y = 0
X = 1	$p_{11}$	$p_{10}$
X = 0	$p_{01}$	$p_{00}$

in our case:

X = 1 if results were deposited (outcome reported), 0 otherwise,  
Y = 1 if the trial has been classified as belonging to a given class (edu, com, gov, hos), 0 otherwise.

**Table 1.** Classification of trials' sponsors.

Research/Educational Institutions ( <b>edu</b> )	Universities, colleges, academia, research institutes	32295 trials (27.2%)
Companies ( <b>com</b> )	pharmaceutical and other for-profit businesses of health care sector	38018 trials (32.1%)
National and Government Organizations ( <b>gov</b> )	federal, municipal, and other government kind of sponsored non-profit organizations	19414 trials (16.4%)
Hospitals & Clinics ( <b>hos</b> )	hospitals & clinics sponsoring clinical trials	17198 trials (14.5%)
Collaborations ( <b>col</b> )	organizations involving different institutions	10011 trials (8.4%)

Brief description and absolute and relative number of trials deposited into ClinicalTrials.gov 01/01/2012.  
doi:10.1371/journal.pone.0037847.t001

We made confidence interval estimate utilizing R software package ([www.r-project.org](http://www.r-project.org)), using *t*-test distribution and 95% confidence level.

## Results and Discussion

As of 01/01/2012 118,602 clinical trials data deposits were made to the depository. They came from 9068 different sources. 35344 (29.8%) of them are assigned as FDA regulated and 25151 (21.2%) as Section 801 controlled substances. 70929 (60%) trials had a treatment purpose.

To get a bigger picture, we calculated how number of started and completed trials progresses year over year from the launch of the depository. 2011 was the only year through the decade of the repository existence when the number of trials completed exceeded the number of trials started (Fig. 2). In 2009 number of trials started came to some kind of saturation. Interestingly, it happened after the last recession (12/2007–6/2009) and the recession itself did not make a notable impact on clinical trials research (*US Business Cycle Expansions and Contractions*, <http://www.nber.org/cycles.html>).

Another interesting feature we have observed, came from the distribution of trials among phases (1–4) for investigated classes (Fig. 3). For companies the number of trials per phase increases to phase 3, then it drops, **gov** and **col** classes have maximum at phase 2, while educational/research institutions have more trials for phase 4 than for phase 3. Currently we do not have an

explanation for this phenomenon but would like to present it for community discussion.

## The Results and Outcome Reporting

In order to better understand drug safety and efficacy, biomedical community has to have clinical trials results not just a brief description. They also very important for establishing effectiveness measures “doing the right trials” [13]. So, availability of clinical results to public became one of the biggest concerns in clinical research [1,5]. Besides, recently investigators have found that reporting, even among registered trials, was done selectively [14]. In response to these concerns, since 2007 FDAAA regulation requires to deposit the study results in case “all of the drugs, biologics, or devices used in that study have been approved by the FDA for at least one use” [4]. At the same time, the use of such registries as ClinicalTrials.gov has been demanded by the International Committee of Medical Journal Editors (ICMJE). As of 2005 the ICMJE has required trial registration before participant enrollment as a prerequisite for publication in any of its member journals [15].

Taking into account described above concerns as well as multiple efforts taken in recent years to achieve research transparency, spread from the FDA requirements to scientific publications in peer reviewed journals [16], we investigated how many trials have the results uploaded into the result database and what factors or regulations were more stimulating than others. Summary statistics for the deposits year-by-year, obeying different imposed requirements is given in Tables 3,4.

Overall, only 4927 (4%) of the deposits had reported clinical results and 6.82% of completed trials (having completion date as of 12/31/2011 or earlier). Certainly cumulative effect of taking into account all the imposed requirements as:


- a trial has to be completed as assigned in its overall status;
- FDA and specifically Section 801 regulations;
- availability of references to a peer reviewed journal (particularly ICMJE members);
- explicit notice of the phase (from 2 to 4);
- description of the study type as ‘interventional’

gives better chance for scientific community and general public to see the results but it still does not seem to be enough. Overall the cumulative requirements returned only about 35% of trials with the deposited results with the maximum 55.56% for trials completed in 2008. That means 3 years ago from the dates of the current analysis, while according to the FDA regulations the results have to be reported within 12 months of the completion date as it is specified in the filings. Section 801 of FDAAA requiring mandatory disclosure of specific clinical trial information

**Table 2.** Correspondence between classification described in this paper and one present in the ClinicalTrials.gov repository.

class (current)	class (original)	number of trials
com	Industry	37076
	Other	942
edu	Other	32118
	Industry	177
gov	U.S. Fed	1974
	NIH	9197
	Industry	776
	Other	7467
	Industry	160
col	Other	9851
hos	Other	17198
unclassified	Other	1666

doi:10.1371/journal.pone.0037847.t002




**Figure 2. Number of trials started and completed each year since launching ClinicalTrials.gov repository.**  
doi:10.1371/journal.pone.0037847.g002

on ClinicalTrials.gov, containing provisions for proof of compliance and authorizing penalties for noncompliance [4], alone has the highest impact on the results depositing. At the same time we note that 4701 trials do not obey any of the investigated requirements, set for the results deposition (or eventually it is not pointed explicitly in the filings) but trials' conductors/sponsors deposited the results anyway.

The next point of our research was to check whether the trials data are different for different responsible institutions (sponsors). We look for how deposition of the results varies among different classes of sponsoring the trials institutions, taking into account all the applied regulations. It appears, government backed organizations less than others comply with the policy to deposit results of clinical trials. Industrial companies demonstrated the best performance in this aspect. And that would be expected taking into account that they have higher fraction of new drug applications

and, therefore, more trials obeying restrictions imposed by the FDA regulations. Detailed statistics is present in Table 5.

Also clinical trials design and reporting policy requires investigators to disclose outcomes of the conducted trials. This has well grounded reasons, at first, trial participants have the right to know about known (from the previous study) risk by participating in trials. Secondly, public availability of this information will benefit next generation of clinical researchers and provides more rational use of healthcare resources. Eventually, outcome reporting may be biased, moreover, some researchers state that the bias occurs regardless of the funding source [17,18], others claim that pharmaceutical industry companies are more prone to the bias [8,19,20]. Namely, the previous research showed that trials' conductors are more enthusiastic for positive outcome reporting in literature [8]. Two aspects make this very likely: firstly, a paper with no results to show or describing something that did not went



**Figure 3. Number of trials assigned to different phases.**  
doi:10.1371/journal.pone.0037847.g003

**Table 3.** Number of completed trials obeying imposed requirements with results and total, deposited into ClinicalTrials.gov.

completion year	Overall			FDA regulated			Section 801		
	with results	total	%	with results	total	%	with results	total	%
2011	169	13945	1.21	114	4475	2.55	93	3134	2.97
2010	894	11732	7.62	593	3899	15.21	491	2649	18.54
2009	1270	10588	11.99	899	3795	23.69	750	2643	28.38
2008	1328	8869	14.97	959	3084	31.1	814	2244	36.27
2007	385	6515	5.91	253	1464	17.28	190	990	19.19
2006	135	4714	2.86	99	848	11.67	56	523	10.71
2005	81	3632	2.23	61	657	9.28	32	408	7.84
2004	103	2076	4.96	90	530	16.98	31	333	9.31
2003	55	1337	4.11	52	389	13.37	16	248	6.45
2002	40	840	4.76	39	179	21.79	6	94	6.38
2001	16	547	2.93	16	84	19.05	9	47	19.15
2000 and before	20	1142	1.75	18	149	12.08	17	82	20.73
<b>total</b>	<b>4496</b>	<b>65937</b>	<b>6.82</b>	<b>3193</b>	<b>19553</b>	<b>16.33</b>	<b>2505</b>	<b>13395</b>	<b>18.7</b>

doi:10.1371/journal.pone.0037847.t003

as expected, may be rejected in the review process, secondly, for companies there is no point to publish a negative outcome, since there is no peer reviewed publications in FDA requirements and a publication for them has rather an advertisement purpose. But depositing results and describing outcome in the repository gives community better chances to see how the trial has been conducted in detail and definitely is not so time and efforts consuming as writing a full paper. How different investigated classes use this opportunity?

4 of 5 assigned classes have very similar outcome reporting statistics close to 3/4 of deposits, while government class provides outcome description significantly more seldom than others. Educational/research class provides more comprehensive outcome description reporting more often not only the primary one but the secondary as well. Overall statistics for outcome reporting

is considerably more optimistic than one for the results data being submitted into the repository. See Table 6 for details.

#### Odds Ratio

Switching from the data already known to an estimate of a future efficiency in the results and outcome reporting we utilized the odds ratio. Conceptually the odds of a successful event are defined as the ratio of the probability of success over the probability of failure. In our case OR allows us to estimate reporting efficiency as the ratio of cases where the results or outcome have been submitted into the depository (success) over cases where this has not been done and compare classes of the suggested classification to see whether the behavior is different depending on what kind of institution is responsible for a conducted trial. Since here we focus

**Table 4.** Number of completed trials obeying imposed requirements with results and total, deposited into ClinicalTrials.gov.

completion year	phases 2-4			with publications			interventional			all requirements together		
	with results	total	%	with results	total	%	with results	total	%	with results	total	%
2011	113	6200	1.82	16	495	3.23	156	11194	1.39	6	61	9.84
2010	638	5445	11.72	71	602	11.79	785	9440	8.32	24	84	28.57
2009	973	5316	18.3	96	659	14.57	1188	8811	13.48	47	111	42.34
2008	1079	4733	22.8	138	710	19.44	1262	7396	17.06	75	135	55.56
2007	306	3815	8.02	57	637	8.95	373	5610	6.65	26	85	30.59
2006	94	2795	3.36	27	454	5.95	131	4062	3.23	16	45	35.56
2005	47	2268	2.07	12	396	3.03	76	3181	2.39	9	46	19.57
2004	46	1323	3.48	15	255	5.88	103	1858	5.54	7	27	25.93
2003	21	824	2.55	5	138	3.62	53	1176	4.51	2	17	11.76
2002	6	434	1.38	3	95	3.16	40	689	5.81	1	5	20
2001	8	291	2.75	1	67	1.49	16	429	3.73	1	4	25
2000 and before	18	485	3.71	6	167	3.59	20	698	2.87	6	14	42.86
<b>total</b>	<b>3349</b>	<b>33929</b>	<b>9.87</b>	<b>447</b>	<b>4675</b>	<b>9.56</b>	<b>4203</b>	<b>54544</b>	<b>7.71</b>	<b>220</b>	<b>634</b>	<b>34.7</b>

doi:10.1371/journal.pone.0037847.t004



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.